全文获取类型
收费全文 | 68227篇 |
免费 | 6443篇 |
国内免费 | 1745篇 |
专业分类
耳鼻咽喉 | 430篇 |
儿科学 | 1066篇 |
妇产科学 | 728篇 |
基础医学 | 4067篇 |
口腔科学 | 880篇 |
临床医学 | 11804篇 |
内科学 | 10128篇 |
皮肤病学 | 228篇 |
神经病学 | 9242篇 |
特种医学 | 16928篇 |
外国民族医学 | 12篇 |
外科学 | 5376篇 |
综合类 | 6617篇 |
一般理论 | 1篇 |
预防医学 | 2182篇 |
眼科学 | 468篇 |
药学 | 3429篇 |
21篇 | |
中国医学 | 748篇 |
肿瘤学 | 2060篇 |
出版年
2024年 | 80篇 |
2023年 | 1213篇 |
2022年 | 1918篇 |
2021年 | 3233篇 |
2020年 | 3198篇 |
2019年 | 2886篇 |
2018年 | 2662篇 |
2017年 | 2724篇 |
2016年 | 2682篇 |
2015年 | 2627篇 |
2014年 | 4717篇 |
2013年 | 4767篇 |
2012年 | 3881篇 |
2011年 | 4383篇 |
2010年 | 3690篇 |
2009年 | 3708篇 |
2008年 | 3687篇 |
2007年 | 3480篇 |
2006年 | 3159篇 |
2005年 | 2861篇 |
2004年 | 2333篇 |
2003年 | 1872篇 |
2002年 | 1473篇 |
2001年 | 1378篇 |
2000年 | 1110篇 |
1999年 | 890篇 |
1998年 | 807篇 |
1997年 | 771篇 |
1996年 | 710篇 |
1995年 | 627篇 |
1994年 | 544篇 |
1993年 | 444篇 |
1992年 | 394篇 |
1991年 | 304篇 |
1990年 | 212篇 |
1989年 | 182篇 |
1988年 | 164篇 |
1987年 | 119篇 |
1986年 | 99篇 |
1985年 | 109篇 |
1984年 | 69篇 |
1983年 | 55篇 |
1982年 | 50篇 |
1981年 | 21篇 |
1980年 | 33篇 |
1979年 | 26篇 |
1978年 | 18篇 |
1977年 | 18篇 |
1976年 | 9篇 |
1974年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 172 毫秒
1.
2.
《Pancreatology》2022,22(8):1175-1180
BackgroundHepatic steatosis has been described as a common finding in adults following total pancreatectomy with islet autotransplantation (TPIAT) but it is unknown if this occurs in children and adolescents.ObjectivesTo define the frequency of post-TPIAT hepatic steatosis in a sample of children and adolescents and to identify clinical predictors of incident steatosis post-TPIAT.MethodsIn this prospective study, consecutive participants at least 1-month post-TPIAT underwent a liver MRI with proton density fat fraction (PDFF) and blood draw at our pediatric academic medical center between April 2021 and January 2022. Comparison clinical pre-TPIAT liver MRI or ultrasound and insulin use and graft function data were extracted from the medical record. T-tests were used for the comparison of means across continuous variables between participants with and without post-TPIAT steatosis.ResultsA total of 20 participants (mean: 13 ± 4 years; 12 female) were evaluated. Mean liver PDFF at research MRI was 7.4 ± 6.2% (range: 2–25%). Seven participants (35%) had categorical hepatic steatosis (PDFF>5%) post-TPIAT, five of whom had pre-TPIAT steatosis, reflecting a 13% (2/15; 95% CI: 2–40%) incidence of post-TPIAT steatosis. Participant characteristics were not significantly different between subgroups with and without post-TPIAT steatosis. Mean PDFF at research MRI was not different between graft function subgroups (7.5% optimal/good vs. 7.3% marginal/failure; p = .96).ConclusionOur study shows a moderate prevalence but low incidence of hepatic steatosis in a small sample of children and adolescents post-TPIAT. This study raises questions about a causal relationship between TPIAT and hepatic steatosis. 相似文献
3.
4.
5.
XI Hui CHENG Guan Liang HU Fei Fei LI Song Nan DENG Xuan ZHOU Yong 《Biomedical and environmental sciences : BES》2022,35(3):206-214
Objective To explore associations between lipoprotein-associated phospholipase A2(Lp-PLA2) and the risk of cardiovascular events in a Chinese population, with a long-term follow-up.Methods A random sample of 2,031 participants(73.6% males, mean age = 60.4 years) was derived from the Asymptomatic Polyvascular Abnormalities Community study(APAC) from 2010 to 2011. Serum Lp-PLA2 levels were determined by enzyme-linked immunosorbent assay(ELISA). The composite endpoint was a combination of first-eve... 相似文献
6.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献
7.
8.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(3):301-310
Background and objectiveTo describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain.Material and methodsRetrospective, observational and multicentric study that included patients initiating treatment with evolocumab (from February 2016 to August 2018), in 15 Nephrology Units in Spain. The demographic and clinical characteristics of the patients, the lipid lowering treatment and the evolution of the lipid profiles between 24 weeks pre-initiation and 12 ± 4 weeks post-initiation of evolocumab were reviewed.ResultsSixty patients were enrolled: 53.3% women; mean (SD) age, 56.9 (12.8) years, 45.0% with familial hypercholesterolemia (FH) (5.0% homozygous and 40.0% heterozygous) and 65.0% with atherosclerotic cardiovascular (CV) disease. The mean (SD) eGFR was 62.6 (30.0) ml/min/1.73 m2 (51.7% of patients had eGFR < 60 ml/min/1.73 m2 [CKD stage > 2]), 50.0% had proteinuria (>300 mg/g) and 10.0% had nephrotic syndrome. Other CV risk factors were hypertension (75.0%), diabetes (25.0%), and smoking (21.7%). A 40.0% of patients were statin intolerant. At evolocumab initiation, 41.7% of patients were on a high-intensity statin, 18.3% on moderate intensity statin and 50.0% were receiving ezetimibe. Mean (SD) LDL-c at evolocumab initiation was 179.7 (62.9) mg/dL (53.4% of patients with LDL-c≥160 mg/dL and 29.3%≥190 mg/dL). After 12 weeks, evolocumab resulted in LDL-c reductions of 60.1%. At week 12, 90.0% of patients reached LDL-c levels <100 mg/dL, 70.0% <70 mg/dL, and 55.0% <55 mg/dL, while mean eGFR levels and statin use were remained stable.ConclusionIn Nephrology Units of Spain, evolocumab was predominantly prescribed in patients with FH, chronic renal disease (CRD>2) and secondary prevention, with LDL-c levels above those recommended by the guidelines. Evolocumab used in clinical practice significantly reduced the LDL-c levels in all patients included in the study. 相似文献
9.
10.